You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
歐康維視生物-B(01477.HK)治療乾眼症藥物臨床試驗具良好安全性和耐受性特徵
阿思達克 02-03 08:11
歐康維視生物-B(01477.HK)公布,公司研發的治療乾眼症的I類新藥OT-202(酪氨酸激(酉每)抑制劑)的I期臨床試驗已經順利完成。 OT-202的I期臨床試驗為一項單次/多次給藥在中國健康成人受試者中的隨機、雙盲、安慰劑對照的安全性、耐受性及藥代動力學特性的臨床試驗。中國I期臨床試驗共入組30例受試者。在I期臨床試驗中,OT-202在健康成人受試者中表現出良好的安全性和耐受性特徵。目前,公司也在推進II期臨床試驗研究。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account